Equities analysts expect ChemoCentryx Inc (NASDAQ:CCXI) to announce earnings per share (EPS) of ($0.27) for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for ChemoCentryx’s earnings, with estimates ranging from ($0.32) to ($0.20). ChemoCentryx posted earnings per share of ($0.22) in the same quarter last year, which indicates a negative year over year growth rate of 22.7%. The firm is expected to issue its next earnings results on Thursday, November 14th.
According to Zacks, analysts expect that ChemoCentryx will report full year earnings of ($1.02) per share for the current financial year, with EPS estimates ranging from ($1.21) to ($0.71). For the next fiscal year, analysts forecast that the company will post earnings of ($1.31) per share, with EPS estimates ranging from ($2.05) to ($0.46). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for ChemoCentryx.
ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $7.17 million during the quarter, compared to analysts’ expectations of $10.08 million. ChemoCentryx had a negative return on equity of 103.61% and a negative net margin of 144.27%.
CCXI stock traded up $0.01 during mid-day trading on Tuesday, hitting $7.22. The company had a trading volume of 5,575 shares, compared to its average volume of 507,569. The company has a market capitalization of $395.31 million, a price-to-earnings ratio of -9.52 and a beta of 1.15. ChemoCentryx has a 12-month low of $6.16 and a 12-month high of $14.98. The company has a quick ratio of 3.57, a current ratio of 3.57 and a debt-to-equity ratio of 0.28. The company has a 50-day moving average price of $6.97 and a 200 day moving average price of $9.65.
Several institutional investors have recently bought and sold shares of CCXI. Tower Research Capital LLC TRC purchased a new stake in shares of ChemoCentryx in the 2nd quarter worth approximately $29,000. Quantamental Technologies LLC purchased a new position in ChemoCentryx during the second quarter valued at $46,000. BNP Paribas Arbitrage SA lifted its holdings in ChemoCentryx by 46,860.0% during the first quarter. BNP Paribas Arbitrage SA now owns 4,696 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 4,686 shares in the last quarter. Aperio Group LLC purchased a new position in ChemoCentryx during the second quarter valued at $82,000. Finally, JPMorgan Chase & Co. lifted its holdings in ChemoCentryx by 104.2% during the second quarter. JPMorgan Chase & Co. now owns 11,191 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 5,710 shares in the last quarter. Hedge funds and other institutional investors own 64.27% of the company’s stock.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Read More: Return On Assets
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.